Santhera Pharmaceuticals announced the appointment of Kristina Timdahl, MD, as Chief Medical Officer and Head of Development and Member of the Executive Management,with effect from January 1, 2017. Kristina Timdahl will replace Nick Coppard, PhD, who will retire in January 2017. As Head Development for over eight years, Nick Coppard was instrumental in the development of the company's lead drug Raxone in multiple indications.